Asian Pacific Journal of Cancer Prevention

Asian Pacific Organization for Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases

  • Yilmaz, Sercan (Department of Radiation Oncology, Diyarbakır State Hospital) ;
  • Adas, Yasemin Guzle (Department of Radiation Oncology, Manisa State Hospital) ;
  • Hicsonmez, Ayse (Department of Radiation Oncology, Medical School, Ankara University) ;
  • Andrieu, Meltem Nalca (Department of Radiation Oncology, Medical School, Ankara University) ;
  • Akyurek, Serap (Department of Radiation Oncology, Medical School, Ankara University) ;
  • Gokce, Saban Cakir (Department of Radiation Oncology, Medical School, Ankara University)
  • Published : 2014.09.15

Abstract

Background: Concurrent chemo-radiotherapy is the recommended standard treatment modality for patients with locally advanced lung cancer. The purpose of three-dimensional conformal radiotherapy (3DCRT) is to minimize normal tissue damage while a high dose can be delivered to the tumor. The most common dose limiting side effect of thoracic RT is radiation pneumonia (RP). In this study we evaluated the relationship between dose-volume histogram parameters and radiation pneumonitis. This study targeted prediction of the possible development of RP and evaluation of the relationship between dose-volume histogram (DVH) parameters and RP in patients undergoing 3DCRT. Materials and Methods: DVHs of 41 lung cancer patients treated with 3DCRT were evaluated with respect to the development of grade ${\geq}2$ RP by excluding gross tumor volume (GTV) and planned target volume (PTV) from total (TL) and ipsilateral (IPSI) lung volume. Results: Were admitted statistically significant for p<0.05. Conclusions: The cut-off values for V5, V13, V20, V30, V45 and the mean dose of TL-GTV; and V13, V20,V30 and the mean dose of TL-PTV were statistically significant for the development of Grade ${\geq}2$ RP. No statistically significant results related to the development of Grade ${\geq}2$ RP were observed for the ipsilateral lung and the evaluation of PTV volume. A controlled and careful evaluation of the dose-volume histograms is important to assess Grade ${\geq}2$ RP development of the lung cancer patients treated with concurrent chemo-radiotherapy. In the light of the obtained data it can be said that RP development may be avoided by the proper analysis of the dose volume histograms and the application of optimal treatment plans.

Keywords

Lung cancer;radiotherapy;radiation pneumonitis;prevention

File

Download PDF

References

  1. Fay M, Tan A, Fisher R, et al (2005). Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. International Journal of Radiation Oncology*Biology*Physics, 61, 1355-63 https://doi.org/10.1016/j.ijrobp.2004.08.025
  2. Fu XL, Huang H, Bentel G, et al (2001).Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys, 50, 899-908. https://doi.org/10.1016/S0360-3016(01)01524-3
  3. Hernando ML, Marks LB, Bentel GC, et al (2001). Radiationinduced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys, 51, 650-9. https://doi.org/10.1016/S0360-3016(01)01685-6
  4. Kim M, Lee J, Ha B, et al (2011). Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer. Radiat Oncol J, 29, 181-90. https://doi.org/10.3857/roj.2011.29.3.181
  5. Kong FM, Hayman JA, Griffith KA, et al (2006). Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis, Int J Radiat Oncol Biol Physics, 65, 1075-86. https://doi.org/10.1016/j.ijrobp.2006.01.051
  6. Kong FM, Hayman JA, Griffith KA, et al (2006). Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis Int J Radiat Oncol Biol Physics, 65, 1075-86. https://doi.org/10.1016/j.ijrobp.2006.01.051
  7. Kong M,Hong SE (2014). Clinical outcome of helical tomotherapy for inoperable non-small cell lung cancer: the kyung hee university medical centre experience. Asian Pacific J Cancer Prev, 15, 1545-49. https://doi.org/10.7314/APJCP.2014.15.4.1545
  8. Lawrence TS, Hayman J, Martel M, et al (1998). Regarding predicting radiation response. Int J Radiat Oncol Biol Phys, 41, 972-3. https://doi.org/10.1016/S0360-3016(98)00142-4
  9. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-65. https://doi.org/10.7314/APJCP.2013.14.4.2663
  10. Malik Ps, Malik A, Deo SV, et al (2014). Underutilization of curative treatment among patients with non small cell lung cancer :experience from a tertiary care centre in india. Asian Pac J Cancer Prev, 15, 2875-78. https://doi.org/10.7314/APJCP.2014.15.6.2875
  11. Mehta V (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction and prevention. Int J Radiation Oncology Biol Phys, 63, 5-24. https://doi.org/10.1016/j.ijrobp.2005.03.047
  12. Ramella S, Trodella L, Mineo TC (2010). Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys, 76, 110-5. https://doi.org/10.1016/j.ijrobp.2009.01.036
  13. Rancati T, Ceresolib GL, Gagliardic G (2003). Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and Oncology, 67, 275-83. https://doi.org/10.1016/S0167-8140(03)00119-1
  14. Rengan R, Chetty I, Decker R, et al (2013). Lung Cancer. In:Halperin EC, Wazer DE, Perez CA et al., Editors. Perez and Brady's Principles and Practice of Radiation Oncology.6th ed.Philadelphia: Lippincott Williams and Wilkins, 938-73.
  15. Schallenkamp JM, Miller RC, Brinkmann DH, et al (2007). Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys, 67, 410-6. https://doi.org/10.1016/j.ijrobp.2006.09.030
  16. Tsujino K, Hirota S, Endo M, et al (2003). Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys, 55, 110-5. https://doi.org/10.1016/S0360-3016(02)03807-5
  17. Wang S, Liao Z, Wei X, et al (2006). Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys, 66, 1399-407. https://doi.org/10.1016/j.ijrobp.2006.07.1337
  18. Wang Z,Qiao YL,Tian X, et al (2012). Toll-like receptor 5 agonismprotects mice from radiation pneumonitis and pulmonary fibrosis. Asian Pac J Cancer Prev, 13, 4763-67. https://doi.org/10.7314/APJCP.2012.13.9.4763

Cited by

  1. Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study vol.32, pp.9, 2015, https://doi.org/10.1007/s12032-015-0672-1
  2. The Potential Role of Lung Ultrasound B-Lines for Detection of Lung Radio-Induced Toxicity in Breast Cancer Patients after Radiation Therapy vol.33, pp.9, 2016, https://doi.org/10.1111/echo.13249